• Explore /
  • Poster
  • / Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis.

Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis.

Abstract Poster

Authors

Daniel Breadner

Daniel Adam Breadner

Schulich School of Medicine and Dentistry, London, ON, Canada

Daniel Adam Breadner , Stephen Welch , Denis Soulieres , Michael Susmoy Sanatani , Paul Klimo , Mary J. MacKenzie , Frances Whiston , Larry Stitt , Anne O'Connell , Mark David Vincent

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 781)

DOI

10.1200/JCO.2017.35.4_suppl.781

Abstract #

781

Poster Bd #

N3

Abstract Disclosures

Similar Posters

First Author: David E. Gerber

First Author: Michael J. Boyer

Poster

2023 ASCO Annual Meeting

Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.

Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.

First Author: Olatunji B. Alese

First Author: Milind M. Javle